Skip to main content
. 2021 May 26;12:628059. doi: 10.3389/fimmu.2021.628059

Figure 4.

Figure 4

aAPC NPs engineered to induce Tregs in vivo suppress lupus-like disease in NSG mice transferred with xenogenic human PBMCs. Six NSG mice per group were left untreated (no transfer) or injected with human PBMCs together with PBS (ctr) or aAPC NPs (see Methods). (A–C) Body weight change (A), clinical disease score (B) and Kaplan-Meier survival curves (C) at the time points indicated on the x axis. *P < 0.05 (aAPC NPs vs controls). (D, E) Comparisons between mice receiving aAPC NPs (NPs) or not (ctr) for skin appearance (D) and tissue histopathology of lung, liver and colon (20 x magnification) (E).